Company Overview

Servatus is an unlisted, public company funded by private investors in 2012. Servatus’ management combines a potent mix of scientific, pharmaceutical and commercial expertise.

Servatus is an exciting business founded on three separate platforms: drug discovery/R&D, commercial manufacturing and OTC health products. Each business is successful in its own right. In addition to autoimmune diseases, Servatus is developing numerous high potential treatments including for insomnia, chronic constipation and acne. The acne and associated skin microbiome products are commercial at an early stage.

The origins of multiple diseases can be linked to the human microbiome; a collection of microbes living symbiotically in our gut and on our skin. Servatus’ core competency is developing treatments for chronic autoimmune conditions, using proprietary microbiome modulating drugs called live biotherapeutics. Servatus is continuing in the proven tradition that the safest and most effective medicines come directly from nature.

Offer Details

Servatus is raising $5M at 15 cents per share, with a 1:1 attaching option at 30 cents (expiring in 24 months). Servatus has about 130 shareholders on its register, with existing shareholders already committing around $2 million toward this round.

Key Investment Highlights:

• Unique Business Model: Servatus offers a diversified, lower-risk life sciences model with substantial short-term upside due to breakthrough live biotherapeutic drugs (LBPs).
• High-Value Drug Development: Our novel LBPs address significant global health problems. Our recent clinical trial for the treatment of rheumatoid arthritis shows the potential to redefine treatment in a $25 billion market.
• Other Breakthrough Therapies: Our platform has also demonstrated efficacy in treating insomnia and IBS-C, both of which are large, unmet needs globally.
• Proprietary OTC Products: Leveraging our microbiome expertise, we have developed high-performance OTC products, including treatments for skin quality and infections.
• State-of-the-Art Manufacturing: Our biopharmaceutical manufacturing capabilities support low-cost, innovative product development across our therapeutic and OTC lines.
• Substantial Prior Investment: Servatus has already attracted $24.7 million from long-standing investors over the past decade.
• R&D Support: We anticipate receiving a $2.7 million Federal Government R&D tax rebate to further support our initiatives.

Comparative Industry Success:

Servatus is well-positioned to deliver significant valuation uplift. Each of our asset lines has the potential to achieve meaningful valuations.

The recent revaluations of Clarity Pharmaceuticals (ASX: CU6) to $2.4 billion and Neuren (ASX: NEU) to $1.7 billion illustrate the significant valuation potential of therapeutic companies that demonstrate successful treatment outcomes and with a path to market.

Application of Funds

• Rheumatopid arthritis clinical trial patient data analytics ($0.6m),
• Rheumatopid arthritis clinical trial extension ($3.5m),
• Expansion of the Biomiq business ($0.5m), and
• Working capital ($0.4m)

More Information

More information about the company can be found on their website: servatus.com.au along with accompanying news medium searches such as https://www.abc.net.au/news/2023-06-28/gut-microbiome-servatus-insomnia-treatment-clinical-trials/102504174

Contact

Naveed Hussain, Senior Corporate Adviser - Novus Capital Limited
Mobile: +61 410 478 786
Email: naveed.hussain@novuscapital.com.au

Downloads